GLP-2/T 30mg

Description

GLP-2/T is a dual GIP and GLP-1 receptor agonist that mimics the body’s natural incretin signaling to enhance insulin sensitivity, reduce appetite, and improve adipose metabolism. Its dual-agonist mechanism delivers superior metabolic regulation compared to single-receptor incretin therapies.

Mechanism of Action:

• GLP-1 receptor activation → Enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes central satiety signaling.
• GIP receptor activation → Amplifies insulin’s metabolic effects and supports lipid metabolism and adipocyte function.

The dual-agonist effect provides more robust and sustained glycemic control with greater adipose reduction than single-agonist approaches.

Research Highlights:

In phase 3 SURPASS trials, GLP-2/T produced up to 22.5% mean body-weight reduction over 72 weeks, alongside significant improvements in HbA1c, lipid profiles, and systemic inflammatory markers.

References: PMID 35701225 | Lancet Diabetes Endocrinol 2022 | Cell Metab 2023

Potential Applications (for research use):

• Obesity and insulin-resistance research
• GIP/GLP-1 receptor synergy and incretin biology studies
• Adipose-tissue metabolism and fat-oxidation models

Stacking Callouts:

Frequently co-researched with MOTS-C or NAD⁺ for mitochondrial and metabolic endurance research protocols.

For laboratory and research use only. Not for human consumption.